Get Skinny

The Medications · November 19, 2026 · 7 min · By Maeve Castellucci

Saxenda microdosing: why a daily liraglutide pen changes the math, and the 16-week test it quietly breaks

Saxenda microdosing borrows an idea from weekly semaglutide and applies it to a drug that leaves the body in about a day. The one dose-ranging trial we have shows every step down the ladder costs real weight, and staying low makes it impossible to run the label's own check on whether the drug is working at all.

A plain white injection pen with a grey cap resting on a folded linen napkin beside a glass of water and two small bowls of berries on a sunlit kitchen counter

Saxenda microdosing is a phrase that started showing up in our reader questions after the first generic version of Saxenda reached pharmacies. The logic people describe is familiar from the semaglutide forums: take less than the full dose, keep most of the appetite control, have fewer side effects, and make each pen last longer. It sounds like the same idea in a different box. It is not, and the reason is pharmacology rather than marketing.

Saxenda is liraglutide, the older GLP-1 medication that Novo Nordisk sold for weight management before Wegovy. It is injected once a day, not once a week, and almost everything people say about microdosing was worked out on weekly drugs. Our broader explainer on microdosing GLP-1s covers the general evidence for semaglutide and tirzepatide. This piece is about what changes when the drug is a daily pen.

The original part of this page is a dose ladder check we have not seen published anywhere else. It lines up each Saxenda pen step against what that exact daily dose produced in the only randomized trial that tested several weight loss doses side by side, then adds the two things a microdoser gives up that nobody mentions: a fast fade between doses, and the loss of the label's built-in efficacy test.

Saxenda microdosing starts from a different place than semaglutide

The first difference is half-life. Semaglutide stays in the body for about a week, so a low weekly dose still builds into a steady level over a month. Liraglutide's half-life is about 13 hours, according to a clinical pharmacology review in Pharmacotherapy. That is why it has to be injected daily. A low daily dose does not slowly accumulate into something bigger. What you inject today is mostly what your body has today, and by tomorrow evening most of it is gone.

In practice, that changes what readers describe. On a low weekly drug, people say appetite control feels muted but even. On a low daily liraglutide dose, people more often describe a curve: quieter hunger in the hours after the shot and noticeably louder hunger by late the next day, especially if the injection runs late. A missed day on liraglutide is felt within about a day. A missed dose on semaglutide often is not felt for several days, which our guide to a missed GLP-1 dose walks through.

The second difference is the pen. The Saxenda pen is built to dial five set doses: 0.6, 1.2, 1.8, 2.4 and 3.0 milligrams. The label, summarized in the MedlinePlus liraglutide monograph, raises the dose one step per week until patients reach 3.0 milligrams. There is no official setting below 0.6. When people online talk about microdosing Saxenda, they usually mean one of two things: staying at 0.6 or 1.2 milligrams long term instead of continuing to climb, or counting the pen's clicks to dial in-between amounts. The first is a real clinical choice some prescribers make for patients who cannot tolerate more. The second is not something the pen was designed or tested for, and any dose error falls entirely on you.

The dose ladder check: what each step actually produced

In 2009, a trial in The Lancet led by Arne Astrup randomized 564 adults with obesity and without diabetes to daily liraglutide at 1.2, 1.8, 2.4 or 3.0 milligrams, to placebo, or to orlistat for 20 weeks, with everyone on the same 500 calorie a day deficit and activity advice. You can read the Astrup dose-ranging trial abstract yourself. It is the closest thing to a direct answer on what lower Saxenda doses do, because every dose was tested as a destination, not just as a step on the way up.

Here is the ladder as prose, with the extra weight loss over placebo in parentheses, which is the part that belongs to the drug rather than to the diet.

At 0.6 milligrams, the starting dose, there is no data. It was never tested as a weight loss dose in that trial. Anyone staying at 0.6 is in completely unstudied territory for weight.

At 1.2 milligrams, average loss was 4.8 kilograms (about 2.0 kilograms more than placebo, which lost 2.8).

At 1.8 milligrams, 5.5 kilograms (about 2.7 more than placebo).

At 2.4 milligrams, 6.3 kilograms (about 3.5 more).

At 3.0 milligrams, the full Saxenda dose, 7.2 kilograms (about 4.4 more).

Read that way, the drug's own contribution at 1.2 milligrams is less than half of what it is at 3.0. Over 20 weeks, the lowest tested dose did only modestly better than orlistat, which produced 4.1 kilograms. The steps are also fairly even. There is no plateau where a lower dose gets you most of the effect. Each step down costs roughly three quarters of a kilogram in this trial, before you even reach doses nobody tested.

The longer trial points the same way. In the 56-week SCALE trial published in the New England Journal of Medicine, 3.0 milligrams of liraglutide produced an average loss of about 8 percent of body weight against 2.6 percent on placebo. That is already a smaller effect than people expect from newer weekly drugs, which is the quotable point here: liraglutide is the GLP-1 with the least room to give up effect, and microdosing gives up effect first.

The 16-week test microdosing breaks

The Saxenda label contains something unusual. If a patient has not lost at least 4 percent of body weight 16 weeks after starting treatment, the label says to stop, because that person is unlikely to get a meaningful benefit. It is a built-in check on whether the drug works for you.

A person who stays at 0.6 or 1.2 milligrams can never run that check. If the weight barely moves, there is no way to tell whether liraglutide does not work for them or whether the dose was simply too low. Many readers then spend months, and real money, in a gray zone. Even with the generic now available, liraglutide is not a cheap daily habit to keep without knowing whether it does anything.

A practical self-check if you are already on a low dose

If you and your prescriber have settled on a low daily dose, three quick questions tell you whether it is doing its job. First, write down your hunger at bedtime on a scale of one to ten for a week. If it climbs every evening and drops after your morning shot, you are feeling the 13-hour fade, and a consistent injection time matters more for you than for a weekly patient. Second, compare your weight at week 16 with your starting weight. Under 4 percent on a low dose is not evidence the drug failed; it is evidence you have not tested it yet. Third, if you are counting clicks, stop and ask your prescriber for a dose the pen actually sets.

There are good reasons to stay at a lower step: persistent nausea, a clinician deciding a maintenance dose holds your weight, or a pairing with other medications. Our piece on titration and why doses start low explains how prescribers weigh that. What the data do not support is treating a daily drug as if it behaves like a weekly one.

The takeaway

Saxenda microdosing is not a gentler version of the semaglutide trend. It is a lower dose of a shorter-acting, more modest drug, with every step down costing measurable weight in the one trial that tested it, and no way to run the label's own test of whether it works. If cost is the reason you are considering it, compare all your options, including whether a different medication or a surgical route makes more sense. Our guide to when weight loss surgery makes sense is a good place to start that comparison. This is general information, not personal medical advice.

More in The Medications

View all →